AAIC 2025 Abstract·26 DecEvaluating AR1001 as Monotherapy from a Phase 2 Study in Mild to Moderate Alzheimer’s Disease PatientsTrial in peopleInterventionsPaper
AAIC 2025 Abstract·24 DecInterlaboratory comparison of amyloid‐beta [AB1‐42], [AB1‐40] and its ratio derived from CSF at two reference laboratories using the lumipulse platformStudy in peopleBiomarkersPaper
AAIC 2025 Abstract·23 DecMultiple Beneficial Effects of AR1001 on Aβ‐Induced Changes in Human MinibrainExperiments in cellsInterventionsPaper